Propanc Biopharma (PPCB)
NASDAQ:PPCB
Want to see PPCB full AI Analyst Report?
PPCB Stock Chart & Stats
$0.22
$0.00(0.00%)
At close: 4:00 PM EST
$0.22
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.30 - $270.25
Previous CloseN/A
Volume127.03K
Average Volume (3M)400.33K
Market Cap
$3.35M
Enterprise Value$2.63M
Total Cash (Recent Filing)$443.70K
Total Debt (Recent Filing)$1.57M
Price to Earnings (P/E)―
Beta-1.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,278,371
10 Day Avg. Volume553,394
30 Day Avg. Volume400,327
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.18
Price to Sales (P/S)0.00
P/FCF Ratio-40.64
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Oncology R&D Targeting Metastatic DiseaseThe company's concentrated R&D focus on metastatic cancer addresses a persistent high unmet medical need and aligns with long-term structural demand for novel oncology therapies. A clear therapeutic niche supports durable development strategy and investor clarity if clinical progress continues.
Low Reported Financial LeverageVery low reported debt versus equity reduces near-term insolvency risk and preserves borrowing capacity, giving management flexibility to fund trials or operations via non-debt routes. Lower leverage materially lessens fixed financial obligations over the medium term.
Improving Free Cash Flow TrendAn improving free cash flow trajectory, even from a weak baseline, indicates early signs of better cash efficiency or reduced burn. If sustained, this trend extends runway and reduces reliance on frequent financings, strengthening the company's operational durability over coming months.
Bears Say
Minimal Revenue And Deep Net LossesThe company remains pre-commercial with negligible revenue while recording material net losses. This structural profile means no internal product cash generation, a persistent need for external capital to fund development, and a long path before profitability, raising execution risk.
Sustained Negative Operating Cash Flow (cash Burn)A multi-million dollar negative operating and free cash flow figure reflects ongoing cash burn tied to R&D and operations. Continued negative cash flow structurally pressures liquidity, forces dependence on capital markets, and increases dilution or funding-constraint risks over the medium term.
Balance Sheet Instability And Dilution RiskHistorical episodes of negative equity and noted recapitalization risk indicate the balance sheet has been unstable. This makes future financing rounds likely to affect existing shareholders and shows a structural vulnerability to dilution that can persist until consistent positive cash generation is achieved.
Propanc Biopharma News
PPCB FAQ
What was Propanc Biopharma’s price range in the past 12 months?
Propanc Biopharma lowest stock price was $1.30 and its highest was $270.25 in the past 12 months.
What is Propanc Biopharma’s market cap?
Propanc Biopharma’s market cap is $3.35M.
When is Propanc Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Propanc Biopharma’s earnings last quarter?
Currently, no data Available
Is Propanc Biopharma overvalued?
According to Wall Street analysts Propanc Biopharma’s price is currently Overvalued.
Does Propanc Biopharma pay dividends?
Propanc Biopharma does not currently pay dividends.
What is Propanc Biopharma’s EPS estimate?
Propanc Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Propanc Biopharma have?
Propanc Biopharma has 2,278,371 shares outstanding.
What happened to Propanc Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Propanc Biopharma?
Currently, no hedge funds are holding shares in PPCB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Propanc Biopharma
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Technical Analysis
Verrica Pharmaceuticals
―
―
―
Barinthus Biotherapeutics
―
Telomir Pharmaceuticals, Inc.
―
Ownership Overview
―
Insiders
―
Mutual Funds
3.67% Other Institutional Investors
96.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---